Cargando…

Reduced Treatment-Emergent Sexual Dysfunction as a Potential Target in the Development of New Antidepressants

Pleasurable sexual activity is an essential component of many human relationships, providing a sense of physical, psychological, and social well-being. Epidemiological and clinical studies show that depressive symptoms and depressive illness are associated with impairments in sexual function and sat...

Descripción completa

Detalles Bibliográficos
Autores principales: Baldwin, David S., Palazzo, M. Carlotta, Masdrakis, Vasilios G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575662/
https://www.ncbi.nlm.nih.gov/pubmed/23431429
http://dx.doi.org/10.1155/2013/256841
_version_ 1782259767165583360
author Baldwin, David S.
Palazzo, M. Carlotta
Masdrakis, Vasilios G.
author_facet Baldwin, David S.
Palazzo, M. Carlotta
Masdrakis, Vasilios G.
author_sort Baldwin, David S.
collection PubMed
description Pleasurable sexual activity is an essential component of many human relationships, providing a sense of physical, psychological, and social well-being. Epidemiological and clinical studies show that depressive symptoms and depressive illness are associated with impairments in sexual function and satisfaction, both in untreated and treated patients. The findings of randomized placebo-controlled trials demonstrate that most of the currently available antidepressant drugs are associated with the development or worsening of sexual dysfunction, in a substantial proportion of patients. Sexual difficulties during antidepressant treatment often resolve as depression lifts but can endure over long periods and may reduce self-esteem and affect mood and relationships adversely. Sexual dysfunction during antidepressant treatment is typically associated with many possible causes, but the risk and type of dysfunction vary with differing compounds and should be considered when making decisions about the relative merits and drawbacks of differing antidepressants. A range of interventions can be considered when managing patients with sexual dysfunction associated with antidepressants, including the prescription of phosphodiesterase-5 inhibitors, but none of these approaches can be considered “ideal.” As treatment-emergent sexual dysfunction is less frequent with certain drugs, presumably related to differences in their pharmacological properties, and because current management approaches are less than ideal, a reduced burden of treatment-emergent sexual dysfunction represents a tolerability target in the development of novel antidepressants.
format Online
Article
Text
id pubmed-3575662
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-35756622013-02-21 Reduced Treatment-Emergent Sexual Dysfunction as a Potential Target in the Development of New Antidepressants Baldwin, David S. Palazzo, M. Carlotta Masdrakis, Vasilios G. Depress Res Treat Review Article Pleasurable sexual activity is an essential component of many human relationships, providing a sense of physical, psychological, and social well-being. Epidemiological and clinical studies show that depressive symptoms and depressive illness are associated with impairments in sexual function and satisfaction, both in untreated and treated patients. The findings of randomized placebo-controlled trials demonstrate that most of the currently available antidepressant drugs are associated with the development or worsening of sexual dysfunction, in a substantial proportion of patients. Sexual difficulties during antidepressant treatment often resolve as depression lifts but can endure over long periods and may reduce self-esteem and affect mood and relationships adversely. Sexual dysfunction during antidepressant treatment is typically associated with many possible causes, but the risk and type of dysfunction vary with differing compounds and should be considered when making decisions about the relative merits and drawbacks of differing antidepressants. A range of interventions can be considered when managing patients with sexual dysfunction associated with antidepressants, including the prescription of phosphodiesterase-5 inhibitors, but none of these approaches can be considered “ideal.” As treatment-emergent sexual dysfunction is less frequent with certain drugs, presumably related to differences in their pharmacological properties, and because current management approaches are less than ideal, a reduced burden of treatment-emergent sexual dysfunction represents a tolerability target in the development of novel antidepressants. Hindawi Publishing Corporation 2013 2013-02-04 /pmc/articles/PMC3575662/ /pubmed/23431429 http://dx.doi.org/10.1155/2013/256841 Text en Copyright © 2013 David S. Baldwin et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Baldwin, David S.
Palazzo, M. Carlotta
Masdrakis, Vasilios G.
Reduced Treatment-Emergent Sexual Dysfunction as a Potential Target in the Development of New Antidepressants
title Reduced Treatment-Emergent Sexual Dysfunction as a Potential Target in the Development of New Antidepressants
title_full Reduced Treatment-Emergent Sexual Dysfunction as a Potential Target in the Development of New Antidepressants
title_fullStr Reduced Treatment-Emergent Sexual Dysfunction as a Potential Target in the Development of New Antidepressants
title_full_unstemmed Reduced Treatment-Emergent Sexual Dysfunction as a Potential Target in the Development of New Antidepressants
title_short Reduced Treatment-Emergent Sexual Dysfunction as a Potential Target in the Development of New Antidepressants
title_sort reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575662/
https://www.ncbi.nlm.nih.gov/pubmed/23431429
http://dx.doi.org/10.1155/2013/256841
work_keys_str_mv AT baldwindavids reducedtreatmentemergentsexualdysfunctionasapotentialtargetinthedevelopmentofnewantidepressants
AT palazzomcarlotta reducedtreatmentemergentsexualdysfunctionasapotentialtargetinthedevelopmentofnewantidepressants
AT masdrakisvasiliosg reducedtreatmentemergentsexualdysfunctionasapotentialtargetinthedevelopmentofnewantidepressants